Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1

Status

Unknown 3Recruiting 3Not yet recruiting 3Active not recruiting 3Terminated 2Completed 2Withdrawn 1Approved for marketing 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 36Neoplasms 8Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3HER2-positive Breast Cancer 3Salivary Gland Neoplasms 2Pathologic Complete Response 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2HER2-positive Early Breast Cancer 2Endometrial Neoplasms 2Colonic Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Resectable HER2-positive Breast Cancer 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplastic Cells, Circulating 1Neoplasms by Site 1Neoplasms by Histologic Type 1Lymphoproliferative Disorders 1Lung Neoplasms 1Liver Neoplasms 1Hemangiosarcoma 1Heart Failure 1

Interventions

Trastuzumab 7pyrotinib 6pertuzumab 3Capecitabine 3tucatinib 2Paclitaxel 2Docetaxel 2trastuzumab deruxtecan 1neratinib 1inavolisib 1Taxoids 1Neoadjuvant Therapy 1Isovaleryl-CoA Dehydrogenase 1Injections 1Genetic Testing 1Drug Therapy 1Carboplatin 1Blood Specimen Collection 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × HER2-positive Breast Cancer × pertuzumab × Clear all
NCT07043725 2026-03-27

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Recruiting
544 enrolled
Breast

HER2-positive Breast Cancer

NCT07377643 2026-02-25

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Phase 3 Recruiting
540 enrolled
Breast

HER2-positive Breast Cancer

NCT06891833 2025-10-02

A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2/3 Recruiting
120 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡